ABVX Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -- compared to Abivax SA's net margin of --. Abivax SA's return on equity of -- beat DBV Technologies SA's return on equity of -280.59%.

Abivax SA has a consensus price target of $155.20, signalling upside risk potential of 27.97%. On the other hand DBV Technologies SA has an analysts' consensus of $40.02 which suggests that it could grow by 90.89%. Given that DBV Technologies SA has higher upside potential than Abivax SA, analysts believe DBV Technologies SA is more attractive than Abivax SA.

Abivax SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.975, suggesting its less volatile than the S&P 500 by 197.455%.

Abivax SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abivax SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Abivax SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Abivax SA's net income of -$179.2M is lower than DBV Technologies SA's net income of -$33M. Notably, Abivax SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abivax SA is -- versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of -- compared to Abivax SA's net margin of -124.5%. Abivax SA's return on equity of -- beat Insmed, Inc.'s return on equity of -192.35%.

Abivax SA has a consensus price target of $155.20, signalling upside risk potential of 27.97%. On the other hand Insmed, Inc. has an analysts' consensus of $212.53 which suggests that it could grow by 42.32%. Given that Insmed, Inc. has higher upside potential than Abivax SA, analysts believe Insmed, Inc. is more attractive than Abivax SA.

Abivax SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.131, suggesting its more volatile than the S&P 500 by 13.112%.

Abivax SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abivax SA pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Abivax SA quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $263.8M. Abivax SA's net income of -$179.2M is higher than Insmed, Inc.'s net income of -$328.5M. Notably, Abivax SA's price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abivax SA is -- versus 48.98x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Inventiva SA has a net margin of -- compared to Abivax SA's net margin of --. Abivax SA's return on equity of -- beat Inventiva SA's return on equity of --.

Abivax SA has a consensus price target of $155.20, signalling upside risk potential of 27.97%. On the other hand Inventiva SA has an analysts' consensus of $15.48 which suggests that it could grow by 138.58%. Given that Inventiva SA has higher upside potential than Abivax SA, analysts believe Inventiva SA is more attractive than Abivax SA.

Abivax SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Inventiva SA has a beta of 0.708, suggesting its less volatile than the S&P 500 by 29.202%.

Abivax SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abivax SA pays -- of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend.

Abivax SA quarterly revenues are --, which are larger than Inventiva SA quarterly revenues of --. Abivax SA's net income of -$179.2M is higher than Inventiva SA's net income of --. Notably, Abivax SA's price-to-earnings ratio is -- while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abivax SA is -- versus 37.78x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Abivax SA's net margin of 34.4%. Abivax SA's return on equity of -- beat Eli Lilly & Co.'s return on equity of 104.39%.

Abivax SA has a consensus price target of $155.20, signalling upside risk potential of 27.97%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,214.34 which suggests that it could grow by 15.43%. Given that Abivax SA has higher upside potential than Eli Lilly & Co., analysts believe Abivax SA is more attractive than Eli Lilly & Co..

Abivax SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.355%.

Abivax SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.73 per share. Abivax SA pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abivax SA quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Abivax SA's net income of -$179.2M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Abivax SA's price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 46.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abivax SA is -- versus 14.70x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.